These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Comparability of FDG PET studies in probable Alzheimer's disease. Herholz K; Perani D; Salmon E; Franck G; Fazio F; Heiss WD; Comar D J Nucl Med; 1993 Sep; 34(9):1460-6. PubMed ID: 8355064 [TBL] [Abstract][Full Text] [Related]
10. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045 [TBL] [Abstract][Full Text] [Related]
11. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. Ishii K; Sasaki M; Kitagaki H; Yamaji S; Sakamoto S; Matsuda K; Mori E J Nucl Med; 1997 Jun; 38(6):925-8. PubMed ID: 9189143 [TBL] [Abstract][Full Text] [Related]
12. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia. Koss E; Friedland RP; Ober BA; Jagust WJ Am J Psychiatry; 1985 May; 142(5):638-40. PubMed ID: 3872604 [TBL] [Abstract][Full Text] [Related]
13. Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Alexander GE; Furey ML; Grady CL; Pietrini P; Brady DR; Mentis MJ; Schapiro MB Am J Psychiatry; 1997 Feb; 154(2):165-72. PubMed ID: 9016263 [TBL] [Abstract][Full Text] [Related]
14. High-resolution technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparison with fluorine-18-FDG PET. Messa C; Perani D; Lucignani G; Zenorini A; Zito F; Rizzo G; Grassi F; Del Sole A; Franceschi M; Gilardi MC J Nucl Med; 1994 Feb; 35(2):210-6. PubMed ID: 8294987 [TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography. Blin J; Piercey MF; Giuffra ME; Mouradian MM; Chase TN J Neurol Sci; 1994 May; 123(1-2):44-51. PubMed ID: 8064320 [TBL] [Abstract][Full Text] [Related]
16. Regional cerebral glucose transport and utilization in Alzheimer's disease. Friedland RP; Jagust WJ; Huesman RH; Koss E; Knittel B; Mathis CA; Ober BA; Mazoyer BM; Budinger TF Neurology; 1989 Nov; 39(11):1427-34. PubMed ID: 2812318 [TBL] [Abstract][Full Text] [Related]
17. Difference of regional cerebral metabolic pattern between presenile and senile dementia of the Alzheimer type: a factor analytic study. Ichimiya A; Herholz K; Mielke R; Kessler J; Slansky I; Heiss WD J Neurol Sci; 1994 May; 123(1-2):11-7. PubMed ID: 8064302 [TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography in Alzheimer's disease. Duara R; Grady C; Haxby J; Sundaram M; Cutler NR; Heston L; Moore A; Schlageter N; Larson S; Rapoport SI Neurology; 1986 Jul; 36(7):879-87. PubMed ID: 3487046 [TBL] [Abstract][Full Text] [Related]
19. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini P; Dani A; Furey ML; Alexander GE; Freo U; Grady CL; Mentis MJ; Mangot D; Simon EW; Horwitz B; Haxby JV; Schapiro MB Am J Psychiatry; 1997 Aug; 154(8):1063-9. PubMed ID: 9247390 [TBL] [Abstract][Full Text] [Related]
20. The fluorodeoxyglucose 18F scan in Alzheimer's disease and multi-infarct dementia. Benson DF; Kuhl DE; Hawkins RA; Phelps ME; Cummings JL; Tsai SY Arch Neurol; 1983 Nov; 40(12):711-4. PubMed ID: 6605139 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]